Header
For Healthcare Professionals
Spiriva Respimat Logo
×

Request Samples

Enter your NPI number to see if you're eligible for samples

 
A doctor and a patient commenting

What is SPIRIVA RESPIMAT?

SPIRIVA RESPIMAT is an anticholinergic indicated for:

  • COPD (2.5mcg): long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations1

  • Asthma (1.25mcg): The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older1

SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm.1

SPIRIVA RESPIMAT contains tiotropium bromide, a long-acting muscarinic antagonist (LAMA), delivered via the Respimat inhaler.1

How does the SPIRIVA RESPIMAT soft mist inhaler help patients?

SPIRIVA RESPIMAT is the only LAMA for the treatment of Asthma (1.25mcg) and COPD (2.5mcg) delivered in soft mist1

The soft mist delivery helps patients with COPD or asthma inhale their medicine1*

  • With the soft mist inhaler, just a slow, deep breath is required–no need to sharply inhale1*

  • Deep lung delivery means nebulized medicine reaches deep into the lungs2,3†

  • *
    As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as the coordination between the actuation of the inhaler and inspiration through the delivery system. The duration of inspiration should be at least as long as the spray duration (1.5 seconds).
  • †
    It is important to note that a correlation between lung deposition and clinical efficacy has not been established.

SPIRIVA RESPIMAT in the Context of COPD and Asthma Management

COPD (2.5mcg):

  • COPD is a progressive disease with uncontrolled airflow limitation and risk of exacerbations.

  • GOLD guidelines recommend LAMA therapy as part of the cornerstone for maintenance treatment.4

  • SPIRIVA RESPIMAT provides proven efficacy in reducing exacerbations.1

Asthma (1.25mcg):

  • Asthma is characterized by chronic airway inflammation and variable airflow obstruction.

  • In adult asthma patients who remain symptomatic on ICS, add SPIRIVA RESPIMAT 1.25mcg.1,2

  • SPIRIVA RESPIMAT is included in GINA guidelines as an add-on option for patients with uncontrolled symptoms despite standard therapy.5

Learn more about soft mist delivery with the SPIRIVA RESPIMAT inhaler

How does SPIRIVA RESPIMAT work?

SPIRIVA RESPIMAT contains tiotropium bromide delivered via the Respimat inhaler.1

  • Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic1

  • In the airways, tiotropium affects the M3-receptors at the smooth muscle leading to bronchodilation1

Why LAMA Therapy Matters:

What is a LAMA:

  • A LAMA is a Long Acting Muscarinic Antagonist — a type of inhaled bronchodilator used primarily to manage chronic respiratory diseases like COPD and, in some cases, asthma.

What it does:

  • LAMAs work by blocking muscarinic receptors in the airway smooth muscle, preventing acetylcholine from causing the airways to constrict. This leads to relaxed, widened airways and improved airflow over an extended period.

Where they are used:

  • COPD (2.5mcg): Is indicated as a long term maintenance therapy.

  • Asthma (1.25mcg): Used as add on therapy for patients with uncontrolled symptoms in addition to background treatment of ICS.

SPIRIVA RESPIMAT is a maintenance treatment for Asthma (1.25mcg)* and COPD (2.5mcg)†

*SPIRIVA RESPIMAT, 1.25mcg, is a long-term, once-daily, prescription maintenance treatment of asthma for people 6 years and older. SPIRIVA RESPIMAT is not a treatment for sudden asthma symptoms.

†SPIRIVA RESPIMAT is not a treatment for sudden symptoms of COPD.

Quick links

INDICATIONS

SPIRIVA RESPIMAT, 2.5mcg, is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for reducing COPD exacerbations.

SPIRIVA RESPIMAT, 1.25mcg, is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.

SPIRIVA RESPIMAT is not indicated for relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product. Immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported.

SPIRIVA RESPIMAT is intended as a once-daily maintenance treatment for COPD and asthma, and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. In the event of an attack, a rapid-acting beta2-agonist should be used.

Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue, or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA RESPIMAT. If such a reaction occurs, discontinue SPIRIVA RESPIMAT at once and consider alternative treatments. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT.

Inhaled medicines, including SPIRIVA RESPIMAT, may cause paradoxical bronchospasm. If this occurs, it should be treated with an inhaled short-acting beta2-agonist, such as albuterol. Treatment with SPIRIVA RESPIMAT should be stopped and other treatments considered.

SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Since dizziness and blurred vision may occur with the use of SPIRIVA RESPIMAT, caution patients about engaging in activities such as driving a vehicle, or operating appliances or machinery.

SPIRIVA RESPIMAT should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA RESPIMAT should be monitored closely for anticholinergic side effects.

The most common adverse reactions >3% incidence and higher than placebo with SPIRIVA RESPIMAT (placebo) in COPD trials were pharyngitis 11.5% (10.1%), cough 5.8% (5.5%), dry mouth 4.1% (1.6%), and sinusitis 3.1% (2.7%).

The most common adverse reactions >2% incidence and higher than placebo with SPIRIVA RESPIMAT (placebo) in asthma trials in adults were pharyngitis 15.9% (12.4%), headache 3.8% (2.7%), bronchitis 3.3% (1.4%), and sinusitis 2.7% (1.4%). The adverse reaction profile for adolescent and pediatric patients was comparable to that observed in adult patients with asthma.

SPIRIVA RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs.

Inform patients not to spray SPIRIVA RESPIMAT into the eyes as this may cause blurring of vision and pupil dilation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

CL-SVR-100065 2.15.2017

Please see full Prescribing Information, including Instructions for Use, for SPIRIVA RESPIMAT.

References

  1. SPIRIVA RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; January 2025.

  2. Wachtel H, Kattenbeck S, Dunne S, Disse B. The RESPIMAT® development story: patient-centered innovation. Pulm Ther. 2017;3(1):1-12.

  3. Anderson P. Use of RESPIMAT® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-259

  4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Accessed, November 18, 2024.  https://goldcopd.org/2025-gold-report/

  5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Accessed March 28, 2025. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf.